Core Insights - Neuralink, co-founded by Elon Musk, has completed a new funding round raising up to $600 million, with a pre-funding valuation of $9 billion [1] - The company aims to develop brain-machine interface (BMI) technology to treat neurological disorders and enhance human capabilities [3] Funding and Valuation - Neuralink's recent funding round aimed to raise at least $500 million from global institutional investors [1] - The company previously completed a $280 million Series D funding round in August 2023 [1] Technology and Development - Neuralink's core technology involves implanting wireless chips in the human skull to connect with the brain, enabling patients with conditions like paralysis and ALS to control devices using their thoughts [1] - The upgraded BMI chip, "Blindsight," is expected to be implanted in human patients by the end of 2025, with initial trials involving 20 to 30 patients [2] - The first human brain implant occurred in January 2024, marking a significant step towards allowing thought-based control of devices [2] Vision and Goals - Neuralink aims to treat various neurological diseases, including Parkinson's and Alzheimer's, while also striving for seamless integration between human cognition and artificial intelligence [3] - The company utilizes advanced, flexible, high-density electrodes and automated surgical robots to simplify the implantation process [3] - Neuralink's vision extends beyond medical applications, seeking to enhance human cognitive and physical abilities and integrate human consciousness with AI [3]